Trial
NCT00297232
Natalizumab (Tysabri) Re-Initiation of Dosing
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Biogen
Collaborators
—
Condition
Relapsing-Remitting Multiple Sclerosis
Intervention
Natalizumab
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-07-15